Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
